The new anti-amyloid drugs for AD are interesting, but an efficacy of 3 points on a 144 scale (2%) does not sound so impressive. We also need to understand ARIA much more
Yngre læge og kommende geriater fra Region Syddanmark. Følg mig i fediverset ved at følge @andreas@apha.dk.
activitypub (7) akutmedicin (17) bluesky (8) covid19dk (404) danskertrut (54) demens (13) dkfedi (39) dkforsvar (8) dkjul (8) dklæger (81) dkmastodon (108) dkmedier (81) dkpol (400) dksund (330) dktwitter (44) dkøko (19) eupol (56) feditips (10) forsvarsforbeholdet (12) ftvalg22 (12) FV22 (10) geriatri (51) influenza (8) Mastodon (16) mastotips (11) nypåmastodon (20) ok21 (18) ok24 (7) Omicron (10) opråbfraplejehjemmet (7) røgfrifremtid (21) somedk (38) StandWithUkraine (44) stophpv (7) sundpol (305) Threads (16) threadsapp (10) twitterX (8) udogsemedDSB (7) UkraineInvasion (51) Ukrainekrise (20) UkraineRussiaWar (7) wegovy (8) wordpress (23) yngrelæger (6)
Jeg kan høre, at du er for ung til at forstå, at NATO lovede Gorbatjev ikke at udvide ind imod…
@andreas Handler det her ikke mere om den sædvanlige udskamning af overvægtige mennesker? Når man siger at de tager resourcer…
@andreas "lagde arm med stormen" 😂
@andreas Lidt mere fralandsvind tak.
@andreas Som min gamle mor (på 82) ofte bemærker det: Man skal nærmest være døende for at komme på plejehjem…
Her kan du se en oversigt over alle de indlæg jeg har lavet på sociale medier gennem tiden.
Agree that we need to characterize ARIA better and make sure doctors know how to predict it and manage it. On the efficacy, I struggle to see why such a change ( which is measurable and consistent on a clinical scale which is not so sensitive to begin with) should be meaningless.
If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.